Biology subjects

Bach, S.

Publications and source records attributed to Bach, S..

4 recordsLinked to original sources

bioRxiv2026

When the Background Matters: Topic-Dependent reference lists in GWAS and Exome Analyses

Gene Ontology (GO) Biological Process overrepresentation analysis is widely used to interpret gene lists from genetic studies, yet results depend critically on the background (universe/reference list) against which enrichment is tested. This paper examines how genome-exome background mismatch alters GO Biological Process significance and induces annotation-driven bias. First, Monte Carlo simulations across multiple input gene list sizes show that enrichment p-values shift systematically when lists sampled from an exome-like universe are tested against a genome background (and vice versa), producing both inflation and deflation of significance depending on GO term composition; these shifts increase with gene list size. Second, applied analyses of gene lists derived from Genome-Wide Association Studies (GWAS) and Whole Exome Studies (WES) across brain, immune, and metabolic domains demonstrate that background choice changes the set of significant GO IDs, yielding reference-specific terms consistent with both Type I errors (false positives) and Type II errors (false negatives). Because genome backgrounds are commonly used by default, the practical risk is greatest when WES-derived lists are analyzed with genome reference lists. To support reproducible best practice, we provide a simple command set for selecting and documenting study-appropriate backgrounds and for assessing sensitivity of GO Biological Process results to the chosen universe.

bioinformatics↗

bioRxiv2024

Transcriptomic analysis of the human habenula in schizophrenia

Pathophysiology of many neuropsychiatric disorders, including schizophrenia (SCZD), is linked to habenula (Hb) function. While pharmacotherapies and deep brain stimulation targeting the Hb are emerging as promising therapeutic treatments, little is known about the cell type-specific transcriptomic organization of the human Hb or how it is altered in SCZD. Here we define the molecular neuroanatomy of the human Hb and identify transcriptomic changes in individuals with SCZD compared to neurotypical controls. Utilizing Hb-enriched postmortem human brain tissue, we performed single nucleus RNA-sequencing (snRNA-seq; n=7 neurotypical donors) and identified 17 molecularly defined Hb cell types across 16,437 nuclei, including 3 medial and 7 lateral Hb populations, several of which were conserved between rodents and humans. Single molecule fluorescent in situ hybridization (smFISH; n=3 neurotypical donors) validated snRNA-seq Hb cell types and mapped their spatial locations. Bulk RNA-sequencing and cell type deconvolution in Hb-enriched tissue from 35 individuals with SCZD and 33 neurotypical controls yielded 45 SCZD-associated differentially expressed genes (DEGs, FDR < 0.05), with 32 (71%) unique to Hb-enriched tissue. eQTL analysis identified 717 independent SNP-gene pairs (FDR < 0.05), where either the SNP is a SCZD risk variant (16 pairs) or the gene is a SCZD DEG (7 pairs). eQTL and SCZD risk colocalization analysis identified 16 colocalized genes. These results identify topographically organized cell types with distinct molecular signatures in the human Hb and demonstrate unique genetic changes associated with SCZD, thereby providing novel molecular insights into the role of Hb in neuropsychiatric disorders. One Sentence SummaryTranscriptomic analysis of the human habenula and identification of molecular changes associated with schizophrenia risk and illness state.

neuroscience↗

bioRxiv2021

Site-specific phosphorylation of PSD-95 dynamically regulates the post-synaptic density as observed by phase separation

Postsynaptic density protein 95 is a key scaffolding protein in the postsynaptic density of excitatory glutamatergic neurons, organizing signaling complexes primarily via its three PSD-95/Discs-large/Zona occludens domains. PSD-95 is regulated by phosphorylation, but technical challenges have limited studies of the molecular details. Here, we genetically introduced site-specific phosphorylations in single, tandem and full-length PSD-95 and generated a total of 11 phosphorylated protein variants. We examined how these phosphorylations affected binding to known interaction partners and the impact on phase separation of PSD-95 complexes, and identified two new phosphorylation sites with opposing effects. Phosphorylation of Ser78 inhibited phase separation with the glutamate receptor subunit GluN2B and the auxiliary protein stargazin, whereas phosphorylation of Ser116 induced phase separation with stargazin only. Thus, by genetically introducing phosphoserine site-specifically and exploring the impact on phase separation, we have provided new insights into the regulation of PSD-95 by phosphorylation and the dynamics of the PSD. Graphical Abstract: Phosphorylation of PSD-95. O_LIIllustration of the interaction between the PDZ domains of PSD-95 and the NMDA receptor (NMDAR) (PDB: 4PE5) at the plasma membrane. PSD-95 interacts with the AMPA receptor (AMPAR) (PDB: 3KG2) through Stargazin (PDB: 5KBU). Using the software Ranch, a model of FL PSD-95 was generated using known structural domains of PSD-95 connected via a fully-flexible linker (PDZ1-2, PDB: 3GSL; PDZ3, PDB: 5JXB; SH3-GK, PDB: 1KJW). C_LIO_LIIllustration of the effect of phosphorylation of PSD-95 on the formation of condensates at the PSD. PSD-95 can phase separate with receptors and intracellular proteins, and phosphorylation is can affect this interaction and lead to alterations, both negative and positive, in the formation of condensates. C_LI

biochemistry↗

bioRxiv2019

Methyl-CpG2-binding protein 2 mediates overlapping mechanisms across brain disorders.

Methyl-CpG binding protein 2 (MeCP2) is a chromatin-binding protein and a modulator of gene expression. Initially identified as an oncogene, MECP2 is now mostly associated to Rett Syndrome, a neurodevelopmental condition, though there is evidence of its influence in other brain disorders.\n\nWe design a procedure that considers several binding properties of MeCP2 and we screen for potential targets across neurological and neuropsychiatric conditions.\n\nWe find MeCP2 target genes associated to a range of disorders, including - among others-Alzheimer Disease, Autism, Attention Deficit Hyperactivity Disorder and Multiple Sclerosis. The analysis of biological mechanisms and pathways modulated by MeCP2s target genes shows that such mechanisms are involved in three main processes: neuronal transmission, immuno-reactivity and development.\n\nThese results suggest that similar symptoms present in different pathologies have a common molecular basis, and that treatments for one condition have potential applications to related disorders.

neuroscience↗